CLAIMS

1. A sterile liquid formulation that has an absolute viscosity of 10 cP or less comprising:

(a) an anti-sclerostin immunoglobulin at a concentration of at least 70 mg/mL;

(b) calcium acetate at a concentration ranging from 1 mM to 20 mM, wherein the anti-sclerostin immunoglobulin comprises amino acid sequences of: (i) SEQ ID NO: 86 and SEQ ID NO: 84; or (ii) SEQ ID NO: 182 and SEQ ID NO: 180; or (iii) SEQ ID NO: 208 and SEQ ID NO: 207; or (iv) SEQ ID NO: 216 and SEQ ID NO: 214; or (v) SEQ ID NO: 220 and SEQ ID NO: 218;

(c) a polyol in an amount ranging from 4% w/v to 6% w/v;

(d) a surfactant.

2. The formulation of claim 1, wherein the formulation comprises a total concentration of acetate between 10 mM and 90 mM.

3. The formulation of claim 1 or claim 2, wherein the formulation comprises a total concentration of acetate between 30 mM and 90 mM or between 30 mM and 75 mM.

4. The formulation of claim 2 or claim 3, wherein the concentration of calcium salt is at least 5 mM and not greater than 15 mM, and the concentration of acetate is at least 50 mM.

5. The formulation of any one of claims 1-3, that has a total osmolarity of less than 350 mOsm/L.

6. The formulation of any one of claims 1-5, wherein the immunoglobulin is present as a concentration of 90 mg/mL.

7. The formulation of any one of claims 1-6, wherein the absolute viscosity of the formulation is 8 cP or less.

8. The formulation of claim 7, wherein the absolute viscosity of the formulation is 6 cP or less.

9. The formulation of any one of claims 1-8, wherein the formulation has a pH ranging from 4.5 to 6.

10. The formulation of claim 9, wherein the formulation has a pH ranging from 5 to 5.5.

11. The formulation of any one of claims 1-10, wherein the concentration of the surfactant is from 0.004% w/v to 0.2% w/v.

12. The formulation of any one of claims 1-11, wherein the surfactant is polysorbate 20.

13. The formulation of any one of claims 1-12, wherein the polyol is sucrose.

14. A sterile liquid formulation for delivering high concentration of an anti-sclerostin immunoglobulin that has an absolute viscosity of 10 cP or less comprising:

(a) an immunoglobulin having heavy chains of SEQ ID NO: 90 and light chains of SEQ ID NO: 88 at a concentration of 90 mg/mL;

(b) calcium acetate at a concentration ranging from 1 mM to 20 mM, wherein the concentration of calcium salt is at least 5 mM and not greater than 15 mM, and the concentration of acetate is at least 50 mM ;

(c) sucrose in an amount ranging from 4% w/v to 6% w/v; and

(d) polysorbate 20 in an amount ranging from 0.004% w/v to 0.2% w/v.

15. Use of a therapeutically effective amount of the formulation of any one of claims 1-14 in the preparation of a medicament for treating osteoporosis in a patient in need thereof.